Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELX/TEZ/IVA effect on glucose tolerance in CF
NCT04599465Phase 3Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Jan 2021
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 3 trial of elexacaftor + tezacaftor + ivacaftor in cystic fibrosis (CF), sponsored by Vertex Pharmaceuticals. Started Jan 2021; status: completed.
02
Drugs
elexacaftor + tezacaftor + ivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT04599465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04599465.